Skip to main content
Clinical Trials/NCT00720759
NCT00720759
Completed
Phase 2

Improving Stroke Rehabilitation: Spacing Effect and D-cycloserine

US Department of Veterans Affairs1 site in 1 country24 target enrollmentJuly 2009

Overview

Phase
Phase 2
Intervention
D-cycloserine + distributed treatment
Conditions
Stroke
Sponsor
US Department of Veterans Affairs
Enrollment
24
Locations
1
Primary Endpoint
Wolf Motor Function Test (Time)
Status
Completed
Last Updated
12 years ago

Overview

Brief Summary

Each year 730,000 Americans experience a stroke. Forty percent are left with significant paralysis of one arm. Certain types of physical therapy, for example constraint induced movement therapy (CIMT), have been shown to be effective in improving arm function. However, for most subjects, improvement is modest. In this trial, we test two approaches that may increase the amount of improvement achieved: 1) distributing treatment over a greater amount of time; and 2) adding a drug, d-cycloserine, which theoretically enhances the molecular mechanisms of learning.

Detailed Description

Each year, 730,000 Americans experience a stroke. Forty percent are left with persistent impairment of upper extremity function. Although scientifically vetted rehabilitation therapies for this impairment are starting to emerge, current treatment is generally unsatisfactory. Therapies that seek to engage neuroplastic mechanisms constitute one approach to this problem. A good example is constraint induced movement therapy (CIMT), a treatment that seeks, through extensive functional task practice, to overcome an acquired intentional predisposition to use the spared arm (learned non-use), and to improve motor function in the affected arm. CIMT has been tested in a host of trials, most recently a multicenter randomized controlled trial (RCT) - the EXCITE trial. These trials have generally demonstrated that on average, the treatment shows efficacy, and the results from the RCT indicate that it is more efficacious than "standard" therapies. However, problems with CIMT can be readily identified that pose research challenges: 1) on average, efficacy is limited; 2) only a fraction of subjects show substantial benefit. We propose to address these two problems in a pilot RCT of 20 subjects that will test two modifications of standard CIMT: 1) addition of a drug, d-cycloserine, that may enhance neuroplasticity by potentiating NMDA-glutamate receptor-mediated learning mechanisms; 2) delivery of a fixed amount of CIMT over a greater number of days, which according to learning research, may enhance long-term retention of gains. All subjects in this trial will receive CIMT. Subjects will be randomized to one of 4 groups: A. CIMT + d-cycloserine, more condensed treatment B. CIMT + d-cycloserine, less condensed treatment C. CIMT + placebo, more condensed treatment D. CIMT + placebo, less condensed treatment The primary outcome measure will be performance on the Wolf Motor Function Test (time) 3 months after completion of treatment.

Registry
clinicaltrials.gov
Start Date
July 2009
End Date
November 2011
Last Updated
12 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Age 21-80,
  • of either sex,
  • diverse ethnic background,
  • s/p a single unilateral hemispheric stroke 6 or more months prior,
  • who meet upper extremity functional criteria for participation in constraint induced movement therapy.

Exclusion Criteria

  • History of more than minor head trauma,
  • subarachnoid hemorrhage,
  • dementia or other neurodegenerative disease,
  • multiple sclerosis,
  • lobar intracerebral hemorrhage,
  • epilepsy,
  • drug or alcohol abuse,
  • serious medical illness,
  • serum creatinine \>1.5,
  • schizophrenia,

Arms & Interventions

Arm 1

D-cycloserine + distributed treatment

Intervention: D-cycloserine + distributed treatment

Arm 2

D-cycloserine + condensed treatment

Intervention: D-cycloserine + condensed treatment

Arm 3

Placebo + distributed treatment

Intervention: Placebo + distributed treatment

Arm 4

Placebo + condensed treatment

Intervention: Placebo + condensed treatment

Outcomes

Primary Outcomes

Wolf Motor Function Test (Time)

Time Frame: 3 months after completion of treatment

The Wolf Motor Function Test (time) score is the average time in seconds taken to perform each of 15 functional tasks ranging in difficulty from putting one's forearm on a table to stacking checkers. Participants are given 120 seconds to perform a task and if they fail, they are scored 120 for that task. Score range on the WMFT-T is 0-120, lower scores being better.

Study Sites (1)

Loading locations...

Similar Trials